📊 XENE Key Takeaways
Is Xenon Pharmaceuticals Inc. (XENE) a Good Investment?
Xenon is a development-stage pharmaceutical company with a strong balance sheet ($546M cash, minimal debt) providing runway for R&D activities, but deteriorating net losses (-47.6% YoY) and complete revenue absence indicate substantial execution risk. Financial viability depends critically on clinical pipeline advancement and regulatory approval achievements.
Xenon Pharmaceuticals Inc. Key Strengths (XENE)
- Exceptional balance sheet with $546M cash and Debt/Equity of 0.01x
- Superior liquidity position (Current Ratio 27.79x) enabling extended development timeline
- Minimal financial distress risk with low absolute debt load ($11M long-term)
XENE Stock Risks: Xenon Pharmaceuticals Inc. Investment Risks
- Zero revenue with undefined commercialization timeline
- Deteriorating profitability trend (-47.6% YoY net loss decline)
- Unsustainable cash burn rate of ~$89M annually dependent on pipeline success
Key Metrics to Watch
- Operating cash flow burn rate and remaining runway duration
- Clinical trial progression milestones and regulatory pathway status
- Revenue generation or partnership announcements indicating commercial traction
Xenon Pharmaceuticals Inc. (XENE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 27.79x current ratio provides a solid financial cushion.
XENE Profit Margin, ROE & Profitability Analysis
XENE vs Healthcare Sector: How Xenon Pharmaceuticals Inc. Compares
How Xenon Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xenon Pharmaceuticals Inc. Stock Overvalued? XENE Valuation Analysis 2026
Based on fundamental analysis, Xenon Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xenon Pharmaceuticals Inc. Balance Sheet: XENE Debt, Cash & Liquidity
XENE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xenon Pharmaceuticals Inc.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-2.73 indicates the company is currently unprofitable.
XENE Revenue Growth, EPS Growth & YoY Performance
XENE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$65.0M | $-0.83 |
| Q3 2025 | N/A | -$47.9M | $-0.81 |
| Q2 2025 | N/A | -$47.9M | $-0.75 |
| Q1 2025 | N/A | -$47.9M | $-0.62 |
| Q3 2023 | $132.0K | -$19.7M | $-0.57 |
| Q2 2023 | $536.0K | -$19.7M | $-0.55 |
| Q1 2023 | $8.8M | -$19.7M | $-0.35 |
| Q3 2022 | $132.0K | -$15.4M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xenon Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
XENE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xenon Pharmaceuticals Inc. (CIK: 0001582313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XENE
What is the AI rating for XENE?
Xenon Pharmaceuticals Inc. (XENE) has an AI grade of B with 42% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XENE's key strengths?
Claude: Exceptional balance sheet with $546M cash and Debt/Equity of 0.01x. Superior liquidity position (Current Ratio 27.79x) enabling extended development timeline.
What are the risks of investing in XENE?
Claude: Zero revenue with undefined commercialization timeline. Deteriorating profitability trend (-47.6% YoY net loss decline).
What is XENE's revenue and growth?
Xenon Pharmaceuticals Inc. reported revenue of $0.0.
Does XENE pay dividends?
Xenon Pharmaceuticals Inc. does not currently pay dividends.
Where can I find XENE SEC filings?
Official SEC filings for Xenon Pharmaceuticals Inc. (CIK: 0001582313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XENE's EPS?
Xenon Pharmaceuticals Inc. has a diluted EPS of $-1.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XENE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Xenon Pharmaceuticals Inc. has a B grade with 42% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XENE stock overvalued or undervalued?
Valuation metrics for XENE: ROE of -7.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is XENE's AI grade for 2026?
Our dual AI analysis gives Xenon Pharmaceuticals Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XENE's free cash flow?
Xenon Pharmaceuticals Inc.'s operating cash flow is $-88.9M, with capital expenditures of $133.0K.
How does XENE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -7.6% (avg: 15%), current ratio 27.79 (avg: 2).